Loading company…
Tokyo-based Modalis Therapeutics develops gene therapy and epigenome editing treatments for genetic disorders.
Founded in 2016 by Haru Morita and based in Tokyo, Japan, Modalis Therapeutics Corporation develops therapies including MDL-207 for Dravet Syndrome and MDL-101 for muscle dystrophies, using CRISPR-based epigenome editing. The products are aimed at healthcare providers and research institutions in the United States and Europe. The company raised JPY 3240 million in its IPO, selling 2.7 million shares at JPY 1200 on the Tokyo Stock Exchange Mothers section. In 2022 it reported revenue of JPY 310,136,000.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in